GSK “Sincerely Apologizes” And Accepts Record $485 Million Fine For China Bribes
This article was originally published in PharmAsia News
The ticket has finally been handed out. Amid a record fine for bribery, GSK says that it remains fully committed to China.
You may also be interested in...
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.